Essential up-to-date intelligence on drugs in R&D development worldwide.
Key Features
-
Over 24,600 drugs in R&D with over 9,600 drugs in active development
-
Over 4,200 biotechnology products
-
Latest phase reached worldwide, with country/region development status in relation to a particular indication
-
Over 3,300 companies, featuring companies' involvement in the development of a drug and their relationships as licensor, licensees or developers
-
Financial background on disease area with sales profiles of the 154 leading therapeutic classes
-
Full commercial summaries, providing a commercial overview, regulatory progress, R&D progress, licensing and partnering deals, analysts sales predictions
-
Full scientific summaries, detailing drug clinical progress
-
36 Searchable fields including mode of administration, indication & therapy class
-
Updated weekly
This information enables you to:
- Track and analyse the latest competitor R&D activities
- Monitor therapy class pipelines to identify future threats to your current portfolio
- Identify new business opportunities for licensing, partnerships or new customers
- Check the pipeline of target companies
- Timetable developments in key product areas
- Examine R&D strategy against market size and growth of leading companies and drugs
More about this offering
Next Steps
